Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston TX YC W20 clinical-stage AV fistula wrap for dialysis patients with 200-patient RCT underway; $22.8M total ($20M Good Growth/Norwest Series A Jun 2024 + $3.6M NIH grant) targeting vascular access failure competing for dialysis market.
VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.